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Neuroticism is a heritable personality trait, characterized by negative emotions such as worrying, 
feelings of guilt, loneliness and being easily hurt. Increased levels of neuroticism are associated 
with poor mental health – development of depression in particular – but it remains uncertain 
whether this association represents a causal effect [1]. Here, we use Mendelian randomization (MR) 
to investigate whether neuroticism is a causal risk factor for development of depression.  
 
MR is an analytic approach to assess the causality of an observed association between a risk factor 
and a clinically relevant outcome [2]. MR is particularly useful in situations where randomized 
controlled trials are not possible and observational studies are likely to be biased due to 
confounding or reverse causality. MR uses genome-wide association study (GWAS) data to identify 
instrumental variables (single nucleotide polymorphisms; SNPs) for a risk factor (here neuroticism) 
that are then tested for association with the outcome of interest (here depression). MR exploits the 
fact that SNP genotypes are randomly allocated during gamete formation (Mendel’s second law) 
and are thus generally not susceptible to reverse causation and confounding [2]. Therefore, MR is 
often referred to as “nature’s randomized control trial”. 
 
We first use summary statistics from a GWAS of neuroticism by Nagel et al. (390,278 samples) 
where individuals were scored based on the 12 neuroticism items from the Eysenck Personality 
Questionnaire (EPQ; see Supplementary Table 1) [3], and from a GWAS of major depression by the 
Psychiatric Genomics Consortium (135,458 cases and 344,901 controls), where diagnosis was 
based on either self-reporting, clinical assessment, or examination of medical records [4]. We 
identified 82 independent, genome-wide significant SNPs for neuroticism; starting with the 7,759 
genome-wide significant (P<5e-8) SNPs from the neuroticism GWAS, we excluded ambiguous 
SNPs (those with alleles A&T or C&G) and those not present in the depression GWAS, then 
thinned so that no pair of SNPs within 3 centiMorgan had correlation-squared >0.001. Collectively, 
the 82 SNPs explain 0.89% of the variation in the EPQ neuroticism score (Supplementary Table 2). 
 
Figure 1 shows that for the 82 SNPs, there is a positive correlation between effect sizes for 
neuroticism and depression. Using inverse-variance weighted regression (red line), as implemented 
in the R package MR-Base [2], we estimated the slope to be 0.25 (SD 0.02), which is significantly 
positive (P<1e-16), and therefore strong evidence that neuroticism is a causal risk factor for 
depression. Specifically, these results indicate that every additional YES answer to the neuroticism 
  
items in the EPQ corresponds to a 0.25 higher log odds ratio (OR) for depression (i.e., a 1.28-times 
higher OR). 
 
Figure 1 approximately here 
 
Underlying MR are three key assumptions [2], which in the context of this study are: (i) all 82 SNPs 
are associated with neuroticism; (ii) the 82 SNPs are uncorrelated with confounders of the 
neuroticism-depression association; (iii) the 82 SNPs affect depression only through neuroticism 
and not directly (no pleiotropy). Our decision to use only SNPs robustly-associated (rather than 
putatively-associated) with neuroticism should ensure (i) is true, while (ii) should be satisfied 
because each individual’s genotypes for the 82 SNPs are randomly assorted during gamete 
formation. To investigate (iii), we performed three sensitivity analyses [2], also reported in Figure 
1. These confirmed that: the slope remains significantly positive (0.17, SD 0.02) if we exclude the 
19 SNPs (those marked in purple) with P<0.05/82 for depression (i.e., those showing strongest 
evidence for pleiotropy); likewise the slope remains significantly positive (0.24, SD 0.02) if we 
instead use weighted-median regression (green line), which is robust provided at least 50% of the 
information comes from non-pleiotropic SNPs; the intercept from Egger Regression (blue line) is 
consistent with zero (0.002, SD 0.006), indicating that there is no strong evidence for directional 
pleiotropy. Additionally, we performed conditional analysis, testing each of the 82 SNPs for 
association including neuroticism score as a covariate (Supplementary Figure 1); only 3 of the SNPs 
are conditionally significant for depression (P<0.05/82), and even if we exclude the 23 SNPs 
nominally significant (P<0.05), the slope remains significantly positive (0.20, SD 0.02). 
 
A separate publication by Nagel et al. provides summary statistics from analyzing each of the 12 
neuroticism items individually (average sample size 371,885) [5]. Supplementary Table 3 reports 
results from MR for each item in turn. The slope from inverse-variance regression is significant 
(P<0.05/12) for 11 of the 12 items, while the remaining item (Do you suffer from “nerves”?) is 
nominally significant (P<0.05). This finding, when interpreted in the context of the modest genetic 
correlations between some of the neuroticism items [5], suggests that it is the broader neuroticism 
syndrome that contributes to the increased risk of depression – and not just single symptoms.   
 
  
In Supplementary Figure 2, we provide results from two additional analyses. Firstly, noting that 
some samples were used in both the neuroticism and MDD GWAS, we verified that the MR results 
were similar if we repeated the analyses using summary statistics from independent sub-GWAS. 
Secondly, we reversed the direction of the analysis, to test whether susceptibility to depression is a 
causal risk factor for neuroticism. Using the same approach as for neuroticism (above), we 
identified 27 independent, genome-wide significant SNPs for depression, which in total explains 
0.35% of susceptibility (measured on the liability scale, assuming a prevalence of 0.14 [4]). Using 
inverse-weighted regression, we estimated the slope to be 0.90 (SD 0.11; P<1e-16); once more, the 
slope remained significantly positive if we excluded the 17 SNPs showing evidence for association 
with neuroticism or if we instead used weighted-median regression, while the intercept from Egger 
Regression was consistent with zero. This indicates that there is also a causal effect going from 
depression to neuroticism, which is consistent with the “scar hypothesis”, whereby depression 
results in a permanent change in an individual’s personality [6]. 
 
In summary, we have provided strong evidence suggesting that neuroticism (both overall and item 
by item) is a causal risk factor for depression. This result is consistent with that from the more 
preliminary MR analysis included in the GWAS by Nagel et al [3]. The main implication of this 
finding is that reducing the degree of neuroticism will tend to reduce the risk of depression. This is 
in agreement with the results of Quilt et al. suggesting that reduction of neuroticism is the 
mechanism by which selective serotonin reuptake inhibitors exert their antidepressant effect [7]. 
Specifically, our results indicate that every 1-point reduction in neuroticism score will reduce log 
odds of depression by 0.25. To put this into context, consider an individual with 50% chance of 
developing depression; were it possible to reduce their neuroticism score by 4 points, their chance 
of depression would reduce to about 25%. Whether such depression risk reduction can be obtained 
via reduction in neuroticism levels should be subjected to further study. 
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Figure 1. Results of Mendelian Randomization (neuroticism to depression)  
 
               
 
For 82 independent, genome-wide significant (P<5e-8) SNPs for neuroticism, points report per-
allele effect sizes for neuroticism and depression (the units are number of YES answers to the 12 
neuroticism items on the Eysenck Personality Questionnaire and log odds ratio, respectively). The 
solid red line indicates the estimated slope from inverse-variance regression (the solid purple line 
indicates the slope if the purple SNPs, those nominally associated with depression, are excluded). 
The solid green line indicates the estimated slope from weighted-median regression; the solid blue 
line indicates the estimated slope from Egger Regression (the vertical blue segment marks a 95% 
confidence interval for the intercept). The four pairs of dashed lines mark 95% confidence intervals 
for the slopes. 
 
 
